Glutamate Carboxypeptidase II
"Glutamate Carboxypeptidase II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A metallocarboxypeptidase that is predominantly expressed as a membrane-bound enzyme. It catalyzes the hydrolysis of an unsubstituted, C-terminal glutamyl residue, typically from PTEROYLPOLYGLUTAMIC ACIDS. It was formerly classified as EC 3.4.19.8.
| Descriptor ID |
D043425
|
| MeSH Number(s) |
D08.811.277.656.350.245.400 D08.811.277.656.350.555.500 D08.811.277.656.675.555.500
|
| Concept/Terms |
Glutamate Carboxypeptidase II- Glutamate Carboxypeptidase II
- Carboxypeptidase II, Glutamate
- FOLH1 Protein
- N-Acetylaspartylglutamate Peptidase
- N Acetylaspartylglutamate Peptidase
- Peptidase, N-Acetylaspartylglutamate
- NAALADase L
- NAAG Peptidase
- NAALADase
- NAALADase II
- Folate Hydrolase I
- Hydrolase I, Folate
- N-Acetylated-alpha-Linked Acidic Dipeptidase
- Acidic Dipeptidase, N-Acetylated-alpha-Linked
- Dipeptidase, N-Acetylated-alpha-Linked Acidic
- N Acetylated alpha Linked Acidic Dipeptidase
|
Below are MeSH descriptors whose meaning is more general than "Glutamate Carboxypeptidase II".
Below are MeSH descriptors whose meaning is more specific than "Glutamate Carboxypeptidase II".
This graph shows the total number of publications written about "Glutamate Carboxypeptidase II" by people in this website by year, and whether "Glutamate Carboxypeptidase II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 3 | 0 | 3 |
| 2007 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glutamate Carboxypeptidase II" by people in Profiles.
-
Nanoplasmid PSMA DNA vaccine primes antitumor immunity and enhances response to PD-1 blockade against prostate cancer. Cancer Lett. 2026 Sep 01; 655:218591.
-
Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther. 2011 Oct; 21(5):299-314.
-
Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res. 2007 Nov 01; 67(21):10528-37.
-
Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen. Clin Cancer Res. 2003 Aug 15; 9(9):3260-71.
-
Evaluation of genetic variants in the reduced folate carrier and in glutamate carboxypeptidase II for spina bifida risk. Mol Genet Metab. 2003 Jul; 79(3):197-200.
-
Effects of the glutamate carboxypeptidase II (GCP2 1561C>T) and reduced folate carrier (RFC1 80G>A) allelic variants on folate and total homocysteine levels in kidney transplant patients. Kidney Int. 2003 Jun; 63(6):2280-5.
-
Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain. J Pharmacol Exp Ther. 2002 Feb; 300(2):662-7.
-
Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 2001 Aug 15; 61(16):6029-33.
-
Rat brain N-acetylated alpha-linked acidic dipeptidase activity. Purification and immunologic characterization. J Biol Chem. 1990 Dec 05; 265(34):21297-301.